IncyteCARES: Connecting to Access, Reimbursement, Education, and Support

IncyteCARES (Connecting to Access, Reimbursement, Education, and Support) assists eligible patients and healthcare providers in obtaining access to its oncology drugs Jakafi or Pemazyre and connects them with continuing support and resources (Table).

IncyteCARES Services

IncyteCARES provides several services for patients who are using Jakafi or Pemazyre, including information about reimbursement support, financial assistance options, educational support, and referrals to patient advocacy organizations.

Jakafi Savings Program and Pemazyre Copay/Coinsurance Program

Through these IncyteCARES programs, eligible patients can receive Jakafi for as little as $0 per month or Pemazyre for a $0 copay, subject to monthly and annual limits.

Patients are eligible if they have commercial or private prescription drug coverage. Patients insured under federal or state government prescription drug programs, including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE, are not eligible. Patients without prescription drug coverage are also not eligible. Patients must be a resident of the United States or a US territory and have a valid prescription for an Incyte medication for an FDA-approved or compendia-recognized use.

To learn more, call IncyteCARES for Jakafi at 855-452-5234, Monday-Friday, 8 am–8 pm ET. For information regarding support for Pemazyre, which is dispensed by Biologics by McKesson specialty pharmacy, call IncyteCARES at 866-708-8806, Monday-Friday, 8 am–8 pm ET. Biologics will work with you and your patient to provide therapeutic expertise and individualized support.

IncyteCARES Patient Assistance Program

Patients without prescription drug coverage for Jakafi or Pemazyre, or those who have been denied claims for treatment with Jakafi or Pemazyre, may be eligible to receive their medication free of charge through the IncyteCARES Patient Assistance Program.

To qualify, patients must:

• Be confirmed as eligible for and enrolled in IncyteCARES for Jakafi or Pemazyre
• Be a resident of the United States or Puerto Rico (for Jakafi) or US territories (for Pemazyre)
• Have a valid prescription for Jakafi or Pemazyre for an FDA-approved or compendia-recognized use.

If underinsured or if uninsured with no coverage, patients may qualify for the Patient Assistance Program if they meet certain household size and annual income criteria or have exhausted their benefits and cannot afford their medication or out-of-pocket expenses. Patients insured under Medicare Part D may qualify by meeting additional criteria and program requirements.

IncyteCARES Temporary Access Program

Eligible patients may be able to receive a free short-term supply of Jakafi or Pemazyre. If a patient’s prescription drug insurer requires more than a 3-day wait for determining coverage approval, a free 30-day supply of the prescribed Incyte medication in the meantime may be provided. No purchase contingencies or other obligations apply.

To qualify, patients must:

• Be confirmed as eligible for and enrolled in IncyteCARES
• Have commercial prescription drug coverage or a healthcare exchange plan. Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TRICARE—are not eligible. Patients without prescription drug coverage are also not eligible
• Be a resident of the United States or Puerto Rico (for Jakafi) or US territories (for Pemazyre)
• Have a valid prescription for an Incyte medication for an FDA-approved use
• Provide proof of the coverage delay.

Nonprofit or Other Support Organizations

Patients who do not qualify for the IncyteCARES programs, including those patients covered by any type of insurance or those without insurance, may be eligible for help with medication costs, treatment-related travel, and other expenses. Referrals to organizations or independent foundations that may offer help can be provided. Eligibility and availability of these assistance programs are determined by the individual organizations.

TABLE Incyte Oncology Drugs